<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62141">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995136</url>
  </required_header>
  <id_info>
    <org_study_id>M-13-047</org_study_id>
    <nct_id>NCT01995136</nct_id>
  </id_info>
  <brief_title>Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma</brief_title>
  <official_title>Investigation of IOP Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004%
      ophthalmic solution (TRAVATAN Z®) in subjects with normal tension glaucoma using TRAVATAN Z®
      monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change from baseline in IOP at 9AM</measure>
    <time_frame>Baseline (Day 0), Up to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>IOP (fluid pressure inside the eye) will be assessed using Goldmann applanation tonometry and is measured in millimeters of mercury (mmHg). Data from 4, 8, and 12 weeks will be pooled, and a negative change indicates an improvement.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Normal Tension Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>TRAVATAN Z®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in both eyes once daily at 9PM for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Ophthalmic Solution 0.004%</intervention_name>
    <description>benzalkonium chloride (BAC) free</description>
    <arm_group_label>TRAVATAN Z®</arm_group_label>
    <other_name>TRAVATAN Z®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of normal tension glaucoma.

          -  Must sign an Informed Consent form.

          -  IOP within protocol-specified range.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Pregnant and lactating women, or women who intend to become pregnant during the study
             period.

          -  Advanced and serious glaucoma, as specified in protocol.

          -  Complicated chronic or recurrent uveitis, scleritis or corneal herpes.

          -  History of ocular trauma, intraocular surgery or laser surgery for the included eye.

          -  Ocular-infection and severe ocular complication.

          -  Best-corrected visual acuity (BCVA) worse than 0.2 decimal.

          -  Difficulty in conducting applanation tonometry for the included eye as determined by
             the doctor.

          -  Severe or serious hypersensitivity to prostaglandin analogues or any ingredients used
             in the study.

          -  Use of IOP lowering ophthalmic solutions other than TRAVATAN Z® or oral carbonic
             anhydrase inhibitor (Diamox, etc.) during the study period.

          -  Use of any adrenocorticosteroids during the study period.

          -  Use of IOP lowering ophthalmic solution within the past 30 days.

          -  Regarded by doctor as not suitable for study participation.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danyel Carr, MS</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Japan, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
